12 July 2024
The European Pharmacopoeia Abolishes Rabbit Testing
The European Pharmacopoeia (Ph. Eur.) has set a new ethical standard by abolishing the traditional Rabbit Pyrogen Test. This decision promotes the development of innovative in-vitro alternatives, such as the monocyte activation test (MAT). Like other states, Switzerland also has its own pharmacopoeia: the Swiss Pharmacopoeia (Pharmacopoeia Helvetica, Ph. Helv.). The texts of the Ph. Eur. form the basis of the Ph. Helv. The Swiss Pharmacopoeia also includes provisions that are only relevant to Switzerland.
For more information, see here.
More News
-
-
Swissmedic: New strategic Approach to minimizing Animal Testing in the Development of Medicinal Products
-
European Medicines Agency: New oral GLP-1 Medicine for Weight Management and Type 2 Diabetes
-
Swissmedic: The new Pharmacopoea Helvetica 13
-
FOPH: Capital Income of Health Insurers for Premium Reduction – current voluntary System deemed sufficient
-
Decision C-6534/2024 of 13 October 2026
-
Swissmedic: Haemovigilance Annual Report 2025
-
Swissmedic: GMP Compliance by foreign Manufacturers - Simplifications for Industry and Clarification of unresolved Issues
-
European Medicines Agency: Clinical Trial Applications Advice Pilot becomes permanent
-
European Medicines Agency: Highlights of the September 2026 Management Board meeting